Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Frohman EM, et al. Among authors: stuart wh. Neurology. 2003 Sep 9;61(5):602-11. doi: 10.1212/01.wnl.0000082654.99838.ef. Neurology. 2003. PMID: 12963748
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Hutchinson M, et al. Among authors: stuart wh. J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. J Neurol. 2009. PMID: 19308305 Free article. Clinical Trial.
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.
Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW; GLANCE Investigators. Goodman AD, et al. Neurology. 2009 Mar 3;72(9):806-12. doi: 10.1212/01.wnl.0000343880.13764.69. Neurology. 2009. PMID: 19255407 Free PMC article. Clinical Trial.
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Goodin DS, et al. Among authors: stuart wh. Neurology. 2002 Jan 22;58(2):169-78. doi: 10.1212/wnl.58.2.169. Neurology. 2002. PMID: 11805241 No abstract available.
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. Balcer LJ, et al. Among authors: stuart wh. Neurology. 2007 Apr 17;68(16):1299-304. doi: 10.1212/01.wnl.0000259521.14704.a8. Neurology. 2007. PMID: 17438220 Clinical Trial.
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Calabresi PA, et al. Among authors: stuart wh. Neurology. 2007 Oct 2;69(14):1391-403. doi: 10.1212/01.wnl.0000277457.17420.b5. Epub 2007 Aug 29. Neurology. 2007. PMID: 17761550 Clinical Trial.
Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.
Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, Pfohl DC, Mills M, Bowen J, Ford C, Heidenreich FR, Jacobs DA, Markowitz CE, Stuart WH, Ying GS, Galetta SL, Maguire MG, Cutter GR. Balcer LJ, et al. Among authors: stuart wh. Neurology. 2003 Nov 25;61(10):1367-73. doi: 10.1212/01.wnl.0000094315.19931.90. Neurology. 2003. PMID: 14638957
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Rudick RA, et al. Among authors: stuart wh. Ann Neurol. 2007 Oct;62(4):335-46. doi: 10.1002/ana.21163. Ann Neurol. 2007. PMID: 17696126 Clinical Trial.
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C. Weinstock-Guttman B, et al. Among authors: stuart wh. J Neurol. 2012 May;259(5):898-905. doi: 10.1007/s00415-011-6275-7. Epub 2011 Oct 19. J Neurol. 2012. PMID: 22008873 Clinical Trial.
34 results